Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial

Xia Meng,1,2 Anxin Wang,1,2 Guojun Zhang,3 Siying Niu,1,2 Wei Li,1,2 Sifei Han,4 Fang Fang,1,2 Xingquan Zhao,1,2 Kehui Dong,1,2 Zening Jin,5 Huaguang Zheng1,2, Kelin Chen,3 Hao Li1,2 Chengyuan Yang1,2, Yongjun Wang1,2

ABSTRACT

Background and purpose Rapid genotyping is useful for guiding early antiplatelet therapy in patients with high-risk nondisabling ischaemic cerebrovascular events (HR-NICE). Conventional genetic testing methods used in CYP2C19 genotype-guided antiplatelet therapy for patients with HR-NICE did not satisfy the needs of the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE)-2 trial. Therefore, we developed the rapid-genotyping GMEX (point-of-care) system to meet the needs of the CHANCE-2 trial.

Methods Healthy individuals and patients with history of cardiovascular diseases (n=408) were enrolled from six centres of the CHANCE-2 trial. We compared the laboratory-based genotypic test results with Sanger sequencing test results for accuracy verification. Next, we demonstrated the accuracy, timeliness and clinical operability of the GMEX system compared with laboratory-based technology (YZY Kit) to verify whether the GMEX system satisfies the needs of the CHANCE-2 trial.

Results Genotypes reported by the GMEX system showed 100% agreement with those determined by using the YZY Kit and Sanger sequencing for all three CYP2C19 alleles (*2, *3 and *17) tested. The average result's turnaround time was 3 min for the GMEX system compared with laboratory-based technology (YZY Kit) which determined the genotype in 60 min.

Conclusions Our data suggest that the GMEX system is a reliable and feasible point-of-care system for rapid CYP2C19 genotyping for the CHANCE-2 trial or related clinical and research applications.

INTRODUCTION

Ischaemic cerebrovascular events are one of the leading causes of death and disability in China. Approximately 65% of ischaemic cerebrovascular events are nondisabling ischaemic cerebrovascular events (NICE), which include transient ischaemic attack (TIA) and minor stroke. The rate of early strokes in these patients with NICE is between 10% and 20%,1,2 which is much higher than previously reported. In particular, patients with high-risk NICE (HR-NICE) require urgent antiplatelet intervention. Our previously published results, from the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial, showed for the first time that aspirin plus clopidogrel taken within 24 hours of symptom onset can significantly reduce the risk of subsequent stroke by 32% compared with aspirin alone in patients with HR-NICE, and that the risk of bleeding did not increase in the clopidogrel-aspirin group. On the basis of the dramatic responses seen in our CHANCE trial, early (within 24 hours) and short-term dual antiplatelet therapy (DAPT) is recommended for patients with NICE. This therapeutic strategy has been incorporated into stroke guidelines worldwide.

However, clopidogrel is a prodrug whose bioactivation is primarily affected by hepatic cytochrome P450 family enzymes, with CYP2C19 playing a predominant role. Numerous genetic polymorphisms exist for CYP2C19. CYP2C19*2 (49.3%) and *3 (13.2%) are the most prevalent loss-of-function (LOF) alleles in the Asian population and contribute to poor bioavailability of active clopidogrel resulting in nonresponsiveness to the antiplatelet therapy. Interestingly, post hoc genetic tests of our CHANCE trial revealed that a large population (58.8%) of patients were CYP2C19*2 and *3 LOF allele carriers and our subsequent analysis revealed that these patients did not significantly benefit from clopidogrel-aspirin treatment compared with aspirin-alone treatment. Meanwhile, patients without CYP2C19*2 and *3 LOF alleles obtained a 17% increase in efficacy of clopidogrel-aspirin treatment compared with aspirin treatment alone. Hence, personalisation of aspirin and clopidogrel DAPT based on CYP2C19 genetic variation may be beneficial for patients receiving this therapeutic strategy.
Genotype-guided antiplatelet therapy is effective and beneficial in the clinic. However, this approach has not yet been clinically evaluated or used to treat cerebrovascular diseases. Therefore, we conceived the CHANCE-2 trial to evaluate the benefit and feasibility of incorporating rapid genotyping to guide early aspirin and clopidogrel DAPT (NCT04078737). The CHANCE-2 trial is a multicenter, double-blinded, double-simulated, randomised, controlled clinical trial in which we plan to screen 10,878 patients by rapid genetic testing within 24 hours of symptom onset and compare the effect of DAPT using clopidogrel and aspirin with that of an alternative DAPT using ticagrelor (a non-CYP2C19 dependent P2Y12 receptor antagonist) and aspirin.

Most conventional genetic testing relies on the patient’s peripheral blood as the source of genomic material. This requires extensive laboratory processing, including sample preparation, genotype detection reagent preparation and empirical interpretation of PCR amplification results. These complicated procedures have dramatically increased the result turnaround time (TAT). Additionally, there are many primary hospitals in the CHANCE-2 trial centres without professional PCR laboratories, and genetic testing cannot be performed in these hospitals. Moreover, prehospital delays are common in China. Our previous CHANCE trial showed that the median time from symptom onset to the trial enrollment was 13 hours. Therefore, our CHANCE-2 trial requires a rapid, sensitive, specific, cost-effective, high-throughput, simple, and user-friendly genotyping system.

We developed a novel GMEX (point-of-care) system for rapid genotyping, and we aimed to evaluate the accuracy and feasibility using the GMEX system for the CHANCE-2 trial or related clinical and research applications.

**METHODS**

**Study design and ethics approval**

We evaluated the performance of the GMEX point-of-care testing system against conventional clinical laboratory-based genomic testing for CYP2C19 genotype detection. We conducted a multicentre study to assess the accuracy and result TAT between the two genotyping methods. Sanger sequencing is a gold standard test and was used to validate the genotyping results from two methods. The Ethics Committee of Beijing Tiantan Hospital Capital Medical University approved this study. All participants provided written informed consent.

**Study subjects**

Healthy individuals and patients with a clinical history of cardiovascular and cerebrovascular diseases were enrolled at six hospitals (Beijing Tiantan Hospital; Kaiyong Central Hospital; the Third People’s Hospital of Tongzhou District, Nantong City; the People’s Hospital of Yixing City; Liaocheng people’s Hospital and Yixing people’s Hospital) between July and August in 2019. Inclusion criteria were healthy individuals by physical examination or patients with the ischaemic attack or other cardiovascular and cerebrovascular diseases. Individuals younger than 18 years of age and pregnant women were excluded.

**GMEX point-of-care genotyping system**

The GMEX point-of-care genotyping system was jointly developed by Chongqing Jingyin Bioscience and the China National Clinical Research Center for Neurological Diseases and was eventually transformed, produced and marketed by Chongqing Jingyin Bioscience. The GMEX system includes a portable DNA analyzer, genotyping reagents and a buccal sample collection kit. The system is user-friendly and can be easily operated, transmitted and analysed and presents an effective and simple approach to genotyping.

The operators associated with the GMEX system were doctors, nurses or clinical researchers. The GMEX system can be operated in the clinical department and bedside. Professional instructors trained all operators on-site and operators were assessed. Those that passed assessments obtained certificates. The training time for each hospital was about 2–4 hours.

The system uses noninvasive sampling by buccal swab at the bedside to improve patient compliance. It integrates automated steps of PCR-based amplification, fluorescent signal detection and genotype determination and is performed at the site of patient care by trained doctors, nurses or clinical researchers, dramatically improving the speed and user-friendliness of genotyping. The system has integrated controls to monitor the performance of a run and ensure ongoing quality of results. The innovative point-of-care test technology is in line with the affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable to end-users criteria proposed by the WHO. It is user-friendly, rapid and robust, equipment-free and deliverable to those who need them.

**Sample collection and processing**

Three buccal swabs and 2 mL peripheral blood in EDTA were collected from healthy individuals and patients. The buccal swabs were either analysed immediately or stored under the manufacturer’s recommended conditions prior to analysis by the GMEX system. Peripheral blood was subjected to analysis using the Human CYP2C19 Gene Polymorphism Detection Kit (ZYMED, Wuhan, China, referred as YZY Kit), a clinically proven method approved by the National Medical Products Administration (NMPA), at the central laboratory of Beijing Tiantan Hospital Capital Medical University and Sanger sequencing at Beijing Genomics Institute (BGI, Beijing, China) for validation. Gender, age and process time were recorded in the data collection form for each subject. Process time of laboratory-based genotyping was only available for subjects whose blood sample was collected at the Beijing Tiantan Hospital, because the blood sample
would need to be transported from other centres to the central laboratory before testing.

**Genotyping by the GMEX system**

Buccal swabs were collected and analysed in accordance with the manufacturer’s instructions. In brief, buccal swab samples taken from the healthy individuals or patients were directly inserted into separately packaged reaction tubes including 25 μL of reaction mixture. This allowed simultaneous mixing of the samples with reagents for detecting CYP2C19 *2, *3 or *17 alleles and sealing of the reaction tubes. The samples were then subjected to analysis by the GMEX DNA analyser using the Taqman assay (Applied Biosystems, Foster City, California, USA). Primers and probes used for three single nucleotide polymorphisms are listed in table 1.

The GMEX DNA analyser is a portable fluorescent PCR machine with 12 reaction wells. Wells cannot be run independently and the temperature increase or decrease and fluorescence excitation or collection are performed at the same time for 12 reaction wells. The GMEX DNA analyser should not be paused while it is running and samples or reagents cannot be added midway.

The PCR conditions used were 95°C for 5 min, followed by 50 cycles of 95°C for 20 s, 62°C–52°C touchdown for 20 s and 72°C for 30 s and 35 cycles of 96°C for 20s, 55°C for 20s and 72°C for 30s. The final extension was performed at 72°C for 5 min. Peripheral blood samples were processed and subsequently analysed using a 3730XL DNA sequencer (Applied Biosystems, Massachusetts, USA).

### Statistical analysis

Patient characteristics were described as medians with IQRs for continuous variables and frequencies and percentages for categorical variables. Kappa statistics were used for the assessment of diagnostic value agreement among the three platforms. The genotype was tested by Hardy-Weinberg equilibrium. All analyses were performed with SAS software V.9.4 (SAS Institute, Cary, North Carolina, USA).

### RESULTS

**On-site performance of the GMEX system**

We compared the TAT and accuracy of our GMEX system to that of the YZY Kit for detecting CYP2C19 *2, *3 and *17 alleles, Sanger sequencing was the gold standard test. To accurately reflect the recruitment process during the CHANCE-2 trial, buccal swabs and peripheral blood samples from 408 subjects (270 men and 138 women) were directly inserted into separately packaged reaction tubes including 25 μL of reaction mixture and subsequently analysed using a 3730XL DNA sequencer (Applied Biosystems, Massachusetts, USA).

### Table 1 Primers and probes used for GMEX system

<table>
<thead>
<tr>
<th>SNP</th>
<th>Primers*</th>
<th>Taqman MGB-probes†</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C19*2</td>
<td>5′-CAGAGCTTGGCATATTGTATCTATA-3′</td>
<td>FAM-TTTCCCGGGAACC</td>
</tr>
<tr>
<td></td>
<td>5′-CGAGGGTTGTGAGTCTCCATC-3′</td>
<td>TexasRed-TTCCCAAG +GAACCC</td>
</tr>
<tr>
<td>CYP2C19*3</td>
<td>5′-CAGCAATTTCTAACTTGAGGA-3′</td>
<td>FAM-CCCCTGG+ATCCAG</td>
</tr>
<tr>
<td></td>
<td>5′-CAATATAGAATTTGGATTTCCCATCAG-3′</td>
<td>TexasRed-ACCCCCCTGAATCCCA</td>
</tr>
<tr>
<td>CYP2C19*17</td>
<td>5′-TGAAACAGAGTGAAGTGCTATAT-3′</td>
<td>FAM-CAGAGATGCTTTG</td>
</tr>
<tr>
<td></td>
<td>5′-GAGGCTTTCTGATGGCCCA-3′</td>
<td>TexasRed-TCAGAGATCTTTG</td>
</tr>
</tbody>
</table>

*Upper line, forward primer; lower line, reverse primer;† Locked nucleic acid.

Forward: 5′-TGCTTCCTGGCATAATGTGAT-3′ and 3′ reverse: 5′-TTTGGGCTGTCCAAAGT-3′, *17 forward: 5′-GCCCTTAGACCAAATTCTC-3′ and *17 reverse: 5′-ATTTACCCCTAATAACACG-3′ were designed to amplify CYP2C19 *2, *3, and *17 genomic fragments. The PCR conditions were 96°C for 5 min, followed by 10 cycles of 96°C for 20 s, 62°C–52°C touchdown for 20 s and 72°C for 30 s and 35 cycles of 96°C for 20 s, 55°C for 20 s and 72°C for 30 s. The final extension was performed at 72°C for 5 min. Peripheral blood samples were processed and subsequently analysed using a 3730XL DNA sequencer (Applied Biosystems, Massachusetts, USA).

**Clinical laboratory-based genotyping**

Genomic DNA from peripheral blood was extracted using the MagNA Pure 96 System (Roche, Basel, Switzerland) and subsequently analysed using the YZY Kit according to the manufacturer’s instructions. In brief, 2 μL (10–30 ng) of genomic DNA was added to a 23 μL reaction tube and subjected to quantitative PCR analysis using the LightCycler 480 PCR system (Roche, Switzerland). According to the criteria set by the YZY Kit manufacturer, the genotype was determined by professional laboratory personnel.

**Validation of CYP2C19 genotypes**

The genotypes of study participants were validated at the BGI Laboratory using Sanger sequencing. PCR primers (*2 forward: 5′-CAGAGGTTGGCATATTGTATCT-3′ and *2 reverse: 5′-GTAAACACAAAACTAGCTAATG-3′, *3 forward: 5′-TGCTTCCTGGCATAATGTGAT-3′ and 3′ reverse: 5′-TTTGGGCTGTCCAAAGT-3′, *17 forward: 5′-GCCCTTAGACCAAATTCTC-3′ and *17 reverse: 5′-ATTTACCCCTAATAACACG-3′) were designed to amplify CYP2C19 *2, *3, and *17 genomic fragments. The PCR conditions were 96°C for 5 min, followed by 10 cycles of 96°C for 20 s, 62°C–52°C touchdown for 20 s and 72°C for 30 s and 35 cycles of 96°C for 20 s, 55°C for 20 s and 72°C for 30 s. The final extension was performed at 72°C for 5 min. Peripheral blood samples were processed and subsequently analysed using a 3730XL DNA sequencer (Applied Biosystems, Massachusetts, USA).

**RESULTS**

We compared the TAT and accuracy of our GMEX system to that of the YZY Kit for detecting CYP2C19 *2, *3 and *17 alleles, Sanger sequencing was the gold standard test. To accurately reflect the recruitment process during the CHANCE-2 trial, buccal swabs and peripheral blood samples from 408 subjects (270 men and 138 women) were directly inserted into separately packaged reaction tubes including 25 μL of reaction mixture and subsequently analysed using a 3730XL DNA sequencer (Applied Biosystems, Massachusetts, USA).

**Statistical analysis**

Patient characteristics were described as medians with IQRs for continuous variables and frequencies and percentages for categorical variables. Kappa statistics were used for the assessment of diagnostic value agreement among the three platforms. The genotype was tested by Hardy-Weinberg equilibrium. All analyses were performed with SAS software V.9.4 (SAS Institute, Cary, North Carolina, USA).

**On-site performance of the GMEX system**

We compared the TAT and accuracy of our GMEX system to that of the YZY Kit for detecting CYP2C19 *2, *3 and *17 alleles, Sanger sequencing was the gold standard test. To accurately reflect the recruitment process during the CHANCE-2 trial, buccal swabs and peripheral blood samples from 408 subjects (270 men and 138 women) with a mean age of 60.8 (IQR: 53.3–67.1) years (age range 22–90 years) were tested on-site and sent to the clinical laboratory for further processing.

The CYP2C19 *2/*3/*17 genotyping results are shown in table 2, and genotypes reported by the GMEX system showed 100% agreement with those determined by both laboratory-based genotyping and Sanger sequencing for all three CYP2C19 alleles tested. Hardy-Weinberg equilibrium revealed that the three genotypes were all consistent with the equilibrium, suggesting that the subjects in this study had no significant natural selection or migration and that they were representative of the population (p>0.05, table 3).
The rapid genotyping approach to clinical CYP2C19 testing is important for acute antiplatelet therapy prescribed after obtaining genotyping results. Our results from a total of 408 patients showed that the average length of workflow time for GMEX system and laboratory-based genotyping were 85.0 (IQR: 85.0–86.0) and 1630.0 (IQR: 354.0–7594.0) min (p<0.001), respectively. The times of sample-to-start, start-to-end and end-to-reports for the GMEX system were 6.0 (IQR: 5.0–6.0), 62.0 (IQR: 61.5–62.0) and 18.0 (IQR: 18.0–18.0) min, respectively. The GMEX system genotyping results were available about 1.5 hour after sample collection and were substantially faster than those produced by laboratory-based genotyping (2–3) days.

**DISCUSSION**

In this study, we applied the GMEX (point-of-care) system, a novel point-of-care genetic testing technology in clinical practice, for the first time. Our results show that this system has demonstrated advantages in clinical practice and satisfies the requirements for the CHANCE-2 trial.

The point-of-care test technology has the advantages of providing fast results, being user-friendly, and having flexible application scenarios. The GMEX (point-of-care) system is widely used in emergency, outpatient and rapid clinical diagnosis. At present, the point-of-care technologies in the field of molecular diagnostics mainly include microfluidic lab-on-a-chip, isothermal amplification and extraction-free direct amplification technologies. The microfluidic lab-on-a-chip technology integrates sample lysis, nucleic acid purification, amplification and detection. Lab-on-a-chip technology has been used to directly analyse saliva samples and has been successfully applied to pathogen detection.\(^{24}\) Isothermal temperature amplification technology uses a constant and moderate temperature, which does not require a large temperature control device, and it has also been used for pathogen detection.\(^{25}\) Extraction-free direct amplification technology relies on a strong anti-inhibition PCR reagent and innovative molecular diagnostic equipment and using this approach oral cells can be directly analysed. Extraction-free direct amplification technology has been approved by The Food and Drug Administration for CYP2C19 genotyping (Spartan RX CYP2C19 Test System).\(^{26,27}\) However, owing to the high testing cost, difficult technical operation and failure to obtain registration approval in the NMPA, none of the products described above is marketable molecular diagnostic point-of-care products in China, with the exception of the GMEX system.

In our study, compared with the laboratory-based genotyping test, the GMEX system can shorten the average TAT time by approximately 20-fold. Our results show the successful application of the GMEX system as a point-of-care model. It not only has the characteristics of rapid detection but also the characteristics of high detection accuracy. The accuracy of the GMEX (point-of-care) system was verified against that of the laboratory-based testing and Sanger sequencing methods. It is worth noting that the accuracy and first-run success rates of GMEX® in Beijing Tiantan Hospital and five primary hospitals were both 100%. None of the patients were retested or excluded owing to incorrect operation or first-run test failure in the GMEX genetic testing group. These data indicate that the accuracy and operability of GMEX would not be affected by hospital rank, operator or geographic regions. The correct operation and positive and daily negative quality control testing before sample testing can better guarantee the validity of this method when it is performed as a point-of-care model.

**Table 2** Comparison of CYP2C19*2, *3 and *17 genotype results obtained with the three methods

<table>
<thead>
<tr>
<th>Genotype results</th>
<th>GMEX system</th>
<th>Laboratory-based genotyping</th>
<th>Sanger sequencing</th>
<th>Kappa statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C19*2</td>
<td>GG 191 (46.81%)</td>
<td>191 (46.81%)</td>
<td>191 (46.81%)</td>
<td>1.000*</td>
</tr>
<tr>
<td></td>
<td>GA 176 (43.14%)</td>
<td>176 (43.14%)</td>
<td>176 (43.14%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA 41 (10.05%)</td>
<td>41 (10.05%)</td>
<td>41 (10.05%)</td>
<td></td>
</tr>
<tr>
<td>CYP2C19*3</td>
<td>GA 45 (11.03%)</td>
<td>45 (11.03%)</td>
<td>45 (11.03%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA 0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CYP2C19*17</td>
<td>CT 9 (2.21%)</td>
<td>9 (2.21%)</td>
<td>9 (2.21%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT 0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Sanger sequencing and laboratory-based genotyping versus Sanger sequencing.

\*GMEX system vs laboratory-based genotyping and GMEX system.

**Table 3** HWE analysis

<table>
<thead>
<tr>
<th>CYP2C19*2</th>
<th>HWE $\chi^2$</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C19*3</td>
<td>1.3899</td>
<td>0.2384</td>
</tr>
<tr>
<td>CYP2C19*17</td>
<td>0.0507</td>
<td>0.8218</td>
</tr>
</tbody>
</table>

HWE, Hardy-Weinberg equilibrium.
There were several limitations of our study. First, we only included subjects 408, and this small sample size may lead to statistical bias. Second, this matching should not be paused, and samples or reagents cannot be added part way through the process. In this study, 59.31% (242/408) of patients carried CYP2C19 LOF alleles, and 35.5% of these patients were taking or intended to take, clopidogrel, which may have caused serious adverse outcomes.15 28 29 Despite increasing recognition of CYP2C19 genetic testing among physicians, there remain a lack of facilities for genetic testing in a large number of grassroots hospitals in China. The GMEX (point-of-care) system can provide a good solution for these hospitals because it is both user-friendly and portable. In conclusion, the GMEX (point-of-care) system resolved the problems of accurate genotyping before the start of antiplatelet therapy and the cost-effectiveness of pharmacogenetic guidance. Our data suggest that the GMEX (point-of-care) system meets the requirement of rapid and accurate genotyping and is a reliable and feasible point-of-care system for rapid CYP2C19 genotyping for the CHANCE-2 trial. Further prospective studies are needed to ascertain whether the rapid genotyping system can improve treatment outcomes.

Acknowledgements
The authors wish to thank Wanting Cai, Wei Xiong, Dan Zhang, Sifei Han for manufacturing GMEX system and providing technical support for clinical validation research.

Contributors
Study concept and design: XM, HL and YW. Drafting of the manuscript: XM, AW and GZ. Statistical analysis: AW. Study supervision and organisation of the project: WL, XZ, KD, ZJ, HZ, HL and YW. Suppling patients: SN, FF, KC and CY. Technical consultant: SH.

Funding
National Science and Technology Major Project (2017ZX09304018).

Competing interests
SH reports consulting fees from Chongqing Jingying Bio-Science Ltd as the external technical consultant of Chongqing Jingying Bio-Science Ltd.

Patient consent for publication
Not required.

Ethics approval
The Ethics Committee of Beijing Tiantan Hospital Capital Medical University approved this study.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request. Data in this article are available upon reasonable request.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Anxin Wang http://orcid.org/0000-0003-4351-2877
Zening Jin http://orcid.org/0000-0001-7392-3920
Huaguang Zheng http://orcid.org/0000-0001-6400-5474
Hao LI http://orcid.org/0000-0002-8591-4105
Chengyu Yang http://orcid.org/0000-0001-6101-6290
Yongjun Wang http://orcid.org/0000-0002-9976-2341

REFERENCES
17 Wang Y. Clopidogrel with aspirin in high-risk patients with acute Non-disabling cerebrovascular events II (CHANCE-2). ClinicalTrials.gov identifier: NCT04078737.

